Iceshot aims to revolutionize the diabetic community
ADDISON, Texas — There's a new reusable applicator that freezes injection sites to reduce pain and discomfort, and it's targeted specifically at people with diabetes.
Iceshot is a personal, topical, dermal numbing unit that is used to numb the skin prior to taking insulin injections. Within a few quick seconds of holding Iceshot to the skin, the pain of the injections is eased dramatically.
Temporarily relieves pain associated with insulin injections.
1. Remove Iceshot unit from freezer and remove cap
2. Hold Iceshot to skin for thirty seconds or until numb
3. Proceed with normal injection method in the Iceshot affected area
4. Recap and place Iceshot unit back in freezer
Iceshot is a registered medical device with the Food and Drug Administration.
Novo Nordisk names new CEO
BAGSVAERD, Denmark – Novo Nordisk on Thursday announced that Lars Rebien Sørensen, president and CEO, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently EVP and head of corporate development, will succeed him, effective Jan. 1, 2017.
The company also announced a number of other executive-level changes, effective immediately.
"Succeeding Lars, who during 16 years as CEO of Novo Nordisk has spearheaded Novo Nordisk into a global, very successful and highly respected pharmaceutical company, is a tall order," stated Göran Ando, chairman Novo Nordisk. "The decision to appoint Lars Fruergaard Jørgensen as new CEO is the result of a rigorous process during which a number of qualified candidates were considered," he continued. "With his track record of creating results, driving change and being a role model for the Novo Nordisk Way of running a company, the Board is confident that he is the perfect successor to Lars Rebien Sørensen. In his new role, he will be charged with leading Novo Nordisk through a time of extraordinary change in healthcare systems around the world, with the company's long-term strategy, the Triple Bottom Line business principle and long-term financial targets as his guiding posts."
The boards of the Novo Nordisk Foundation and the Foundation's holding company, Novo A/S, will nominate Lars Rebien Sørensen to become a member of the two boards in March 2017.
In addition, Novo Nordisk announced that Jakob Riis, currently EVP and head of Region China, Pacific & Marketing, is appointed EVP and head of North America Operations. He succeeds Jesper Høiland, who steps down from executive management and whose future role in Novo Nordisk will be announced at a later date.
Maziar Mike Doustdar, currently EVP and head of International Operations, continues in this role, but with enlarged responsibility for an expanded International Operations unit, now covering all territories except for North America and organized in the following five regions: Europe; Latin America; Africa, Asia, Middle East & Oceania; Japan & Korea; and Region China.
Jerzy Gruhn, currently EVP and head of Europe, steps down from executive management and will continue as head of Europe, now as SVP, reporting to Maziar Mike Doustdar.
Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, U.S. and Japan. In 2004 he was appointed SVP for IT & Corporate Development. In January 2013 he was appointed EVP and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over additional responsibilities for Corporate People & Organisation and Business Assurance.
Lars Fruergaard Jørgensen is chairman of the board of NNE Pharmaplan A/S, Denmark. He earned an MSc in Finance and Business Administration from Aarhus School of Business, Aarhus University, Denmark, in 1991. He is a Danish national, born November 1966.
FDA reaches agreement with generics industry on new GDUFA commitments
WASHINGTON — The Food and Drug Administration and the generic drug manufacturing industry —including representatives of generic pharmaceutical manufacturers, active pharmaceutical ingredient manufacturers and contract manufacturing organizations — have reached agreement on a package of program enhancements and resource commitments to reauthorize the Generic Drug User Fee Amendments of 2012 (GDUFA), which are set to expire next year.
“GPhA and its members are pleased to conclude the first reauthorization negotiations to update the Generic Drug User Fee Amendments," stated David Gaugh, SVP sciences and regulatory affairs, GPhA. "The commitments outlined in GDUFA II enable the FDA to continue delivering on its promise to protect public health by ensuring access to safe and effective generic medicines."
“The PBOA hails the successful conclusion of the GDUFA II negotiation, and we believe that industry, the FDA and patients will see great benefits from the program during the next five-year period," added Gil Roth, president Pharma & Biopharma Outsourcing Association. "PBOA’s presence at the negotiating table ensured that Contract Manufacturing Organizations were represented in the new iteration of this critical program.”
The generics industry is optimistic that the provisions of this agreement will streamline approvals by assigning goal dates to all ANDAs to assure that no submissions from GDUFA I are left behind. It will also provide the FDA with additional resources, improving transparency and accountability in order to enhance the ability of the FDA to meet GDUFA II goals. Process changes and staff additions have been positive steps thus far, and the addition of enhanced performance reporting sets an even stronger foundation for translating FDA actions on generic applications to approvals.
GDUFA I was passed in 2012 as part of the Food and Drug Administration Safety and Innovation Act with the goals of improving safety, access and transparency within the generic sector. The new version of this industry-funded program, includes key improvements, metrics and resource provisions intended to streamline the review process for Abbreviated New Drug Applications (ANDAs), enhance FDA’s inspection infrastructure and increase accountability, while providing relief for small businesses.